Sequenced CV Interventions for Lifetime Benefit

As the second Roundtable in the PRIME-Heart Initiative series, this meeting focused on translating earlier risk identification into action. Experts explored how clinicians can sequence and prioritize evidence-based prevention strategies to reduce lifetime ASCVD risk, with an emphasis on timely, stage-appropriate intervention. Discussions examined barriers to early action, gaps between guidelines and real-world practice, and practical approaches to implementing risk-guided prevention in routine care.

Explore the Roundtable materials, key takeaways, and insights that will help inform future guidance and resources supporting proactive cardiovascular prevention.

• Sequenced CV Interventions for Lifetime Benefit: Primary Prevention Across the CKM Spectrum Roundtable
• Key Takeaways

← Back

The PRIME-Heart Initiative is supported by:
Amgen, AstraZeneca, Boehringer Ingelheim, HeartFlow, Novartis, Novo Nordisk